Mutation profile and programmed death ligand 1 status of patients with non‐small cell lung cancer diagnosed with “adenocarcinoma” and “non‐small cell carcinoma favor adenocarcinoma”
Thoracic Cancer · 2024
DOI: 10.1111/1759-7714.15214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Naoko Shigeta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan. Hauptthemen laut MEDLINE: Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
The terminology for lung cancer diagnosis in small biopsies was adopted in the 2015 World Health Organization classification. If non‐small cell lung cancer (NSCLC) has no clear adenocarcinoma (AD) or squamous cell carcinoma morphology, the tumor is further classified based on mucin or immunohistochemical staining as NSCLC favor AD (NFAD), NSCLC favor squamous cell carcinoma, or NSCLC not otherwise specified. Since this new term was defined, the difference between AD and NFAD has not yet been fully explored. This study aimed to examine the differences in clinical background, gene alteration frequency, and programmed death ligand 1 (PD‐L1) expression.
Methods
We included patients diagnosed with AD or NFAD with small samples, and who underwent testing with the Oncomine Dx target test between August 2019 and April 2023 in Kanagawa Cancer Center.
Results
This study comprised 268 patients. A total of 96 patients underwent surgery after AD or NFAD diagnosis. The clinical stage was more advanced and pathological N0 was lower in NFAD than in AD. The pathology of the surgical specimens revealed that solid predominant AD was significantly more common in NFAD than in AD ( p < 0.001). In both AD and NFAD, EGFR mutation was the most frequent gene alteration, followed by KRAS mutation. The frequency of EGFR mutations was significantly higher in AD than in NFAD. PD‐L1 expression was significantly higher in NFAD than in AD ( p < 0.001).
Conclusion
This study shows a clear difference between AD and NFAD in terms of cancer progression, pathological features of the main tumor, genetic characteristics, and PD‐L1 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan.
- Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan.
- Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
ORCID-Profile: Naoko Shigeta, Shuji Murakami, Tetsuya Isaka, Kanako Shinada, Haruhiro Saito
Zitieren
APA
Shigeta, N., Yokose, T., Murakami, S., Isaka, T., Shinada, K., Yoshioka, E., Narita, A., Katakura, K., Kondo, T., Kato, T., Nagashima, T., Saito, H., & Ito, H. (2024). Mutation profile and programmed death ligand 1 status of patients with non‐small cell lung cancer diagnosed with “adenocarcinoma” and “non‐small cell carcinoma favor adenocarcinoma”. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15214
Vancouver
Shigeta N, Yokose T, Murakami S, Isaka T, Shinada K, Yoshioka E, et al. Mutation profile and programmed death ligand 1 status of patients with non‐small cell lung cancer diagnosed with “adenocarcinoma” and “non‐small cell carcinoma favor adenocarcinoma”. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15214
BibTeX
@article{Shigeta2024,
author = {Shigeta, Naoko and Yokose, Tomoyuki and Murakami, Shuji and Isaka, Tetsuya and Shinada, Kanako and Yoshioka, Emi and Narita, Atsuya and Katakura, Kengo and Kondo, Tetsuro and Kato, Terufumi and Nagashima, Takuya and Saito, Haruhiro and Ito, Hiroyuki},
title = {Mutation profile and programmed death ligand 1 status of patients with non‐small cell lung cancer diagnosed with “adenocarcinoma” and “non‐small cell carcinoma favor adenocarcinoma”},
journal = {Thoracic Cancer},
year = {2024},
doi = {10.1111/1759-7714.15214}
}
EUVIMED